Navigation Links
BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
Date:11/20/2008

LYNBROOK, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Thomas Wegman, will present at the upcoming Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008, at 4:30pm ET at the New York Palace Hotel in New York, NY.

A live webcast of the presentation can be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BSTC&item_id=2021200.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in June 2008. More information about the company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
4. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
5. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
6. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
7. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
8. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
9. Wound Management Technologies, Inc. Announces a Published Case Study
10. Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
11. China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... A mechanised blue dye test alternat...ging quality assurance one step closer for pharma-...eak testing machine developed by Sepha for use ...ed in several local and global pharma-companies su...uality assurance and productivity improvements on ...
(Date:11/25/2009)... Ambassador to Speak at Economic Club...ada (Vocus) November 25, 2009 -- Ambassador to Spe...d Appia, French Ambassador for International Inves...e Agency ,To view a biography of David Appia go to... Appia is available to meet with press to discuss ...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportlink... is available in its catalogue: ,, Brazil Bioe..., http://www.reportlinker.com/p0165503/Brazil-Bio... ,, Brazil Bioethanol Market Analysis and Fore...vides detailed analysis and forecasts of the globa...
(Date:11/24/2009)... Ambassador to also Visit Detroit , ...-- , , ,Who: David Appia, French Ambassador for In...e Invest in France Agency, , , , ,What: Ambassado... recent pro-business initiatives adopted by France...emic landscape for innovation and development., , ...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3French Ambassador for International Investment to Visit Toronto December 11 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10
...et Revenues - $33.9 million vs. $24.0 million in Q...41.5%, Q3 2008 Diluted Net Income per Share - $0... increase of 85.7% Q3 2008 Operating Inco...New Bookings of $43.0 million vs. $35.5 million in...ogy,Inc. (eRT), (Nasdaq: ERES ), a leading provid...
..., Mass., Oct. 30 Idenix,Pharmaceuticals, Inc. (Na...,in the discovery and development of drugs for the...eases, today reported unaudited financial results,...ber 30, 2008. At,September 30, 2008, Idenix,s cash...ed approximately $60.1 million., 2008 Year-to-Dat...
..., N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX ) an...r ended,September 30, 2008., Medarex,s net loss f...million, or ($0.36) per share, as compared to a ne...the third quarter of 2007. Included in the 2008,re...0.04) per share, for,stock based compensation reco...
Other Biology Technology:eResearchTechnology Reports Third Quarter 2008 Results 2eResearchTechnology Reports Third Quarter 2008 Results 3eResearchTechnology Reports Third Quarter 2008 Results 4eResearchTechnology Reports Third Quarter 2008 Results 5eResearchTechnology Reports Third Quarter 2008 Results 6eResearchTechnology Reports Third Quarter 2008 Results 7eResearchTechnology Reports Third Quarter 2008 Results 8eResearchTechnology Reports Third Quarter 2008 Results 9eResearchTechnology Reports Third Quarter 2008 Results 10Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 5Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 6Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 7Medarex Announces 2008 Third Quarter Financial Results 2Medarex Announces 2008 Third Quarter Financial Results 3Medarex Announces 2008 Third Quarter Financial Results 4Medarex Announces 2008 Third Quarter Financial Results 5Medarex Announces 2008 Third Quarter Financial Results 6Medarex Announces 2008 Third Quarter Financial Results 7Medarex Announces 2008 Third Quarter Financial Results 8Medarex Announces 2008 Third Quarter Financial Results 9
(Date:11/24/2009)...h . , The presence of increased body fat, an...es in the blood, hinders the loss and maintenance ...the University of Navarra conducted by Estbaliz Go...cy. , The project, entitled "A nutrigenetic and ...ody weight and inflammation," examines how the ind...
(Date:11/23/2009)...iated strain of the deadly superbug MRSAan infecti...ioticsposes a far greater health threat than previ...according to a study in the December issue of Eme... easily picked up in fitness centers, schools, and... burden of MRSA within hospitals, the report found...
(Date:11/23/2009)...me of day matters to forest trees dealing with dro...rch team led by Professor Malcolm Campbell, Univer...esearch and colleagues in the department of cell a... Capitalizing on their previous work to decode the...ined how poplar trees use their 45,000 genes to re...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Time of day matters to thirsty trees, U of T researcher discovers 2Case Western Reserve University receives 243 7M NIH grant to study autonomic nervous system link to painful bladder syndrome 52572 1Case Western Reserve University receives 243 7M NIH grant to study autonomic nervous system link to painful bladder syndrome 52572 2Short stressful events may improve working memory 9335 1Short stressful events may improve working memory 9335 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 1Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 3
...er patients without incurring side effects such as... method, produced at the University of Bath, Engla... the chemotherapy drug which are then implanted in...ese fibres are bio-degradable and compatible with ...d by the patient,s body. They gradually turn from ...
...ve damage caused by diabetes has shown promising r...The University of Manchester team has discovered t... stimulating a person,s genes may prevent nerve da...he disease. , The positive preclinical results ?r...nce that the research could lead to a new treatmen...
...amoeba acts as an incubator for MRSA bacteria. As ... this discovery has implications for the infection...ngle cell amoeba, Acanthamoeba polyphagam commonly...engulfs pathogens such as MRSA. However, instead o...replicates whilst inside the amoeba. Prof Michael ...
Other Biology News:New device could cut chemotherapy deaths 2Trial success for diabetic nerve therapy 2
Label IT Tracker BiotinIntracellular Nucleic Acid Localization Kit from Mirus Bio Corporation
...ion's NanoMate 100 robotic system and disposable E...capabilities of electrospray mass spectrometers fo...ate with MS allows users to either speed analysis ...ptide mapping applications, or long acquisition ti...
...olute QPCR SYBR Green Mixes are optimised for SYBR...essary to perform Quantitative PCR, with the excep...en Mix contains optimal levels of active SYBR Gree...n a proprietary reaction buffer that enables detec...
Rabbit Anti-Mouse Vitronectin Polyclonal Antibody, Unconjugated from Abcam
Biology Products: